Literature DB >> 30728669

Gene Editing in Clinical Practice: Where are We?

Rama Devi Mittal1.   

Abstract

Multitude of gene-altering capabilities in combination with ease of design and low cost have all led to the adoption of the sophisticated and yet simple gene editing system that are clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (CRISPR). The CRISPR/Cas9 system holds promise for the correction of deleterious mutations by taking advantage of the homology directed repair pathway and by supplying a correction template to the affected patient's cells. CRISPR is a tool that allows researchers to edit genes very precisely, easily and quickly. It does this by harnessing a mechanism that already existed in bacteria. Basically, there's a protein that acts like a scissors and cuts the DNA, and there's an RNA molecule that directs the scissors to any point on the genome one wants which results basically a word processor for genes. An entire gene can be taken out, put one in, or even edit just a single letter within a gene. Several platforms for molecular scissors that enable targeted genome engineering have been developed, including zinc-finger nucleases, transcription activator-like effector nucleases and, most recently, CRISPR/CRISPR-associated-9 (Cas9). The CRISPR/Cas9 system's simplicity, facile engineering and amenability to multiplexing make it the system of choice for many applications. CRISPR/Cas9 has been used to generate disease models to study genetic diseases. Improvements are urgently needed for various aspects of the CRISPR/Cas9 system, including the system's precision, delivery and control over the outcome of the repair process. However, there are still some glitches to be mended like how to regulate gene drives and its safeguards. The creation of gene knockouts is one of the first and most widely used applications of the CRISPR-Cas9 system. Nuclease-active Cas9 creates a double-strand break at the single guide RNA-targeted locus. These breaks can be repaired by homologous recombination, which can be used to introduce new mutations. When the double-strand break is repaired by the error-prone nonhomologous end joining process, indels are introduced which can produce frame shifts and stop codons, leading to functional knockout of the gene. Precedence modification have to be done on mechanism of CRISPR/Cas9, including its biochemical and structural implications incorporating the latest improvements in the CRISPR/Cas9 system, especially Cas9 protein modifications for customization. Current applications, where the versatile CRISPR/Cas9 system is to be used to edit the genome, epigenome, or RNA of various organisms is debated. Although CRISPR/Cas9 allows convenient genome editing accompanied by many benefits, one should not ignore the significant ethical and biosafety concerns that it raises. Conclusively lot of prospective applications and challenges of several promising techniques adapted from CRISPR/Cas9. Is discussed. Although many mechanistic questions remain to be answered and several challenges to be addressed yet, the use of CRISPR-Cas9-based genome technologies will increase our knowledge of disease process and their treatment in near future. Undoubtedly this field is revolutionizing in current era and may open new vistas in the treatment of fatal genetic disease.

Entities:  

Keywords:  CASPR Cas9 systems; Ethics; Gene targeting; Gene therapy embryo; Genome editing; Molecular scissors; Nucleases; Palindromic repeats; Potential pitfalls

Year:  2019        PMID: 30728669      PMCID: PMC6346614          DOI: 10.1007/s12291-018-0804-4

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  35 in total

Review 1.  CRISPR-Cas9: a new and promising player in gene therapy.

Authors:  Lu Xiao-Jie; Xue Hui-Ying; Ke Zun-Ping; Chen Jin-Lian; Ji Li-Juan
Journal:  J Med Genet       Date:  2015-02-24       Impact factor: 6.318

Review 2.  De novo mutations in human genetic disease.

Authors:  Joris A Veltman; Han G Brunner
Journal:  Nat Rev Genet       Date:  2012-07-18       Impact factor: 53.242

Review 3.  Targeted genome editing tools for disease modeling and gene therapy.

Authors:  Mi Cai; Yi Yang
Journal:  Curr Gene Ther       Date:  2014-02       Impact factor: 4.391

4.  CRISPR-Cas9 knockin mice for genome editing and cancer modeling.

Authors:  Randall J Platt; Sidi Chen; Yang Zhou; Michael J Yim; Lukasz Swiech; Hannah R Kempton; James E Dahlman; Oren Parnas; Thomas M Eisenhaure; Marko Jovanovic; Daniel B Graham; Siddharth Jhunjhunwala; Matthias Heidenreich; Ramnik J Xavier; Robert Langer; Daniel G Anderson; Nir Hacohen; Aviv Regev; Guoping Feng; Phillip A Sharp; Feng Zhang
Journal:  Cell       Date:  2014-09-25       Impact factor: 41.582

5.  Genome engineering using the CRISPR-Cas9 system.

Authors:  F Ann Ran; Patrick D Hsu; Jason Wright; Vineeta Agarwala; David A Scott; Feng Zhang
Journal:  Nat Protoc       Date:  2013-10-24       Impact factor: 13.491

6.  Multiplex genome engineering using CRISPR/Cas systems.

Authors:  Le Cong; F Ann Ran; David Cox; Shuailiang Lin; Robert Barretto; Naomi Habib; Patrick D Hsu; Xuebing Wu; Wenyan Jiang; Luciano A Marraffini; Feng Zhang
Journal:  Science       Date:  2013-01-03       Impact factor: 47.728

7.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

8.  Biotechnology. A prudent path forward for genomic engineering and germline gene modification.

Authors:  David Baltimore; Paul Berg; Michael Botchan; Dana Carroll; R Alta Charo; George Church; Jacob E Corn; George Q Daley; Jennifer A Doudna; Marsha Fenner; Henry T Greely; Martin Jinek; G Steven Martin; Edward Penhoet; Jennifer Puck; Samuel H Sternberg; Jonathan S Weissman; Keith R Yamamoto
Journal:  Science       Date:  2015-03-19       Impact factor: 47.728

9.  Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining.

Authors:  Takeshi Maruyama; Stephanie K Dougan; Matthias C Truttmann; Angelina M Bilate; Jessica R Ingram; Hidde L Ploegh
Journal:  Nat Biotechnol       Date:  2015-03-23       Impact factor: 54.908

10.  Allele-specific genome editing and correction of disease-associated phenotypes in rats using the CRISPR-Cas platform.

Authors:  K Yoshimi; T Kaneko; B Voigt; T Mashimo
Journal:  Nat Commun       Date:  2014-06-26       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.